Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report

Figure 1 Radionuclide bone imaging indicated progression on bone. A: Before the treatment; B: Three months later.

Figure 2 Prostate-specific membrane antigen positron emission tomography – computed tomography examination showed abnormal prostate-specific membrane antigen aggregation was significantly reduced, and bone metastasis was significantly improved compared with baseline. A, B: Before the treatment; C, D: Three months later.

Figure 3 Prostate-specific antigen curve.